BioTime, Inc. is a clinical-stage biotechnology company in the field of regenerative medicine headquartered in Alameda, California. BioTime stock is traded on the New York Stock Exchange Market Exchange, ticker symbol BTX. BioTime focuses primarily on two areas: stem cell technology and products for use in regenerative medicine, focusing on areas such as oncology, orthopedics, blood diseases, and blood plasma volume expanders for use in surgery and treatment of traumatic injuries. BioTime’s products currently on the market include Hextend, a blood plasma volume expander which is manufactured and distributed by Hospira (NYSE: HSP) and research reagents. Hospira was acquired by Pfizer in February 2015. The company is in a pivitol clinical trial for age-related macular degeneration (AMD). On November 3, 2014 BioTimes subsidiary Cell Cure Neurosciences received FDA authorization to initiate a phase I/IIa trial of OpRegen, an embryonic stem cell-derived treatment for the dry-AMD.